A New Public-Private Strategy to Combat Malaria and Tuberculosis
Thursday, April 17, 2014
Although deaths caused by malaria and TB worldwide have considerably decreased, and each nearly halved in the past two decades according to the World Health Organization, mortality cases remain concentrated in mostly low-income countries, and funding for research and development to treat and cure the diseases is slow and unsteady. TB especially continues to present new challenges, as multi-drug resistant TB is now on the rise.
Pharmaceutical companies alone cannot invest the hundreds of millions of dollars in research and development for malaria, TB and other neglected diseases, since they cannot expect to see a quick return on the investment, says B.T. Slingsby, the executive director of the Global Health Innovation and Technology Fund.
- Health Care